Published Date: 08 Mar 2023
Hospitals in New Mexico, Texas and Oklahoma are the first to call for a new rural hospital payment model that shifts services from inpatients to outpatients and emergency patients.
Read Full NewsDESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.
A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?
High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.
Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.
1.
More cancer cases in areas where incarceration rates are high: Study
2.
Dasatinib Fails to Improve Outcomes in CBF-AML
3.
Housing aid linked to lower medical financial hardship among US renters with cancer
4.
Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.
5.
Pain’s Toll: Frailty Risk for Childhood Cancer Survivors
1.
Integrated Trends in Hematology for Modern Medicine
2.
Understanding the Importance of CA125: A Comprehensive Guide
3.
A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51%
4.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
5.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Common Cancer Myths Debunked
2.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
4.
Oropharyngeal Cancer in Relation to HPV Status
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation